David H Kirn

David H Kirn


Are you David H Kirn?   Register this Author

Register author
David H Kirn

David H Kirn

Publications by authors named "David H Kirn"

Are you David H Kirn?   Register this Author



Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms.

Cancer Res 2018 Feb 19;78(4):922-937. Epub 2017 Dec 19.

UCSF Helen Diller Family Comprehensive Cancer Center, Cardiovascular Research Institute and Department of Anatomy, University of California, San Francisco, San Francisco, California.

View Article
February 2018

The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594).

Oncolytic Virother 2015 28;4:25-31. Epub 2015 Jan 28.

SillaJen Inc, Seoul, South Korea.

View Article
August 2016

Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic.

Curr Opin Virol 2015 Aug 17;13:49-54. Epub 2015 Apr 17.

SillaJen Biotherapeutics, 450 Sansome St, Suite 650, San Francisco, CA 94111, United States.

View Article
August 2015

Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans.

Sci Transl Med 2013 May;5(185):185ra63

Pusan National University and Medical Research Institute, Pusan National University, 1-10 Ami-Dong, Seo-Gu, Busan 602-739, South Korea.

View Article
May 2013

Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594.

Curr Pharm Biotechnol 2012 Jul;13(9):1768-72

Jennerex Inc. San Francisco, CA, USA.

View Article
July 2012

Redemption for the field of oncolytic virotherapy.

David H Kirn

Mol Ther 2011 Apr;19(4):627-8

View Article
April 2011

Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses.

Cytokine Growth Factor Rev 2010 Apr-Jun;21(2-3):135-41. Epub 2010 Mar 24.

Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.

View Article
September 2010

Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval.

Cytokine Growth Factor Rev 2010 Apr-Jun;21(2-3):85-9. Epub 2010 May 15.

Jennerex Inc., San Francisco, CA, USA.

View Article
September 2010

Oncolytic virotherapy for advanced liver tumours.

J Cell Mol Med 2009 Jul 23;13(7):1238-47. Epub 2008 Oct 23.

Department of Pathology and Immunology, Washington University in Saint Louis, Saint Louis, MO, USA.

View Article
July 2009

Targeted genetic and viral therapy for advanced head and neck cancers.

Drug Discov Today 2009 Jun 17;14(11-12):570-8. Epub 2009 Mar 17.

Cancer Center, Taipei Veterans General Hospital, School of Medicine, National Yang-Ming University, Taipei, Taiwan.

View Article
June 2009

Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer.

Nat Rev Cancer 2009 Jan;9(1):64-71

Jennerex Biotherapeutics Inc., San Francisco, California 94105, USA .

View Article
January 2009

The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma.

Mol Ther 2008 Sep 15;16(9):1637-42. Epub 2008 Jul 15.

JENNEREX Biotherapeutics, San Francisco, California 94105, USA.

View Article
September 2008

Development of targeted oncolytic virotherapeutics through translational research.

Expert Opin Biol Ther 2008 Sep;8(9):1381-91

Jennerex Biotherapeutics, One Market Street, Spear Tower, Suite 2260, San Francisco, CA 94105, USA.

View Article
September 2008

Oncolytic adenoviruses for cancer gene therapy.

Methods Mol Biol 2008 ;433:243-58

Brain Tumor Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

View Article
August 2008

Enhancing poxvirus oncolytic effects through increased spread and immune evasion.

Cancer Res 2008 Apr;68(7):2071-5

Jennerex Biotherapeutics, Ltd., San Francisco, California, USA.

View Article
April 2008

Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.

PLoS Med 2007 Dec;4(12):e353

Jennerex Biotherapeutics, San Francisco, California, United States of America.

View Article
December 2007

Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963.

J Clin Invest 2007 Nov;117(11):3350-8

Department of Pediatrics and Bio-X Program, James H. Clark Center, Stanford University School of Medicine, Stanford, California, USA.

View Article
November 2007

From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development.

Curr Cancer Drug Targets 2007 Mar;7(2):133-9

JENNEREX Biotherapeutics, San Francisco, CA 94105, USA.

View Article
March 2007

Selective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacy.

Mol Ther 2006 May 8;13(5):938-46. Epub 2006 Feb 8.

Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA.

View Article
May 2006

The use of oncolytic vaccinia viruses in the treatment of cancer: a new role for an old ally?

Curr Gene Ther 2005 Aug;5(4):429-43

JENNEREX Biotherapeutics, Mill Valley, CA, USA.

View Article
August 2005

Vaccinia virus and oncolytic virotherapy of cancer.

Curr Opin Mol Ther 2005 Aug;7(4):359-65

Stanford University School of Medicine, Department of Pediatrics and Bio-X Program, Stanford, CA 94305, USA.

View Article
August 2005

Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus.

Expert Opin Biol Ther 2004 Aug;4(8):1307-21

Bio-X Program, Dept of Pediatrics, School of Medicine, Stanford University, CA, USA.

View Article
August 2004

Interleukin-1beta and tumour necrosis factor-alpha promote the transformation of human immortalised mesothelial cells by erionite.

Int J Oncol 2004 Jul;25(1):173-8

Molecular Oncology Unit, Cancer Research UK, Imperial College London Hammersmith Hospital, London W12 0NN, UK.

View Article
July 2004

Analysis of a three-way race between tumor growth, a replication-competent virus and an immune response.

Bull Math Biol 2004 Jul;66(4):605-25

School of Industrial and Systems Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA.

View Article
July 2004

Replication-selective oncolytic adenoviruses.

Methods Mol Med 2004 ;90:71-90

Viral and Genetic Therapy Programme, Cancer Research UK and Imperial College School of Medicine, Hammersmith Hospital, London, UK.

View Article
March 2004

Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery.

Cancer Res 2003 Mar;63(6):1317-24

Sloan School of Management, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.

View Article
March 2003

A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma.

Clin Cancer Res 2003 Feb;9(2):555-61

Jonsson Comprehensive Cancer Center, University of California at Los Angeles School of Medicine, Los Angeles, California 90095, USA.

View Article
February 2003

Liver-directed viral therapy for cancer p53-targeted adenoviruses and beyond.

Surg Oncol Clin N Am 2002 Jul;11(3):571-88, vi

Department of Surgery, University of California-San Francisco, 533 Parnassus Avenue, U-372, San Francisco, CA 94143-0790, USA.

View Article
July 2002